Kessler Topaz Meltzer & Check said it is investigating potential federal securities law violations by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) after the biotech company cut full-year 2026 TTR product sales guidance in its July 30 second-quarter results and its shares fell more than 28%. Alnylam said the reduction reflected lessons from the initial launch phase in the evolving ATTR-CM (a heart disease caused by amyloid deposits) market, including a normalization in second-line volume after pent-up demand from patients waiting for a new therapy was met, lowering projected TTR net product revenue by about $200 million. The GlobeNewswire-distributed statement urged investors who bought Alnylam securities and suffered losses to contact the firm, which said there is no cost or obligation to speak with an attorney and that affected investors may have legal rights under federal securities laws.